We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes.
- Authors
Shams'ili, Setareh; De Beukelaar, Janet; Gratama, Jan; Hooijkaas, Herbert; Van Den Bent, Martin; Van't Veer, Mars; Sillevis Smitt, Peter
- Abstract
Anti-CD20 monoclonal antibody (rituximab) is effectively used in the treatment of B-cell lymphomas. Recent reports in the literature suggest that antibody associated autoimmune disorders may respond to rituximab. We therefore treated nine patients with anti-Hu or anti-Yo associated paraneoplastic neurological syndromes (PNS) with a maximum of four monthly IV infusions of rituximab (375mg/m2). In this uncontrolled, unblinded trial of rituximab, three patients improved ≥1 point on the Rankin Scale (RS). One patient with limbic encephalitis improved dramatically (RS from 5 to 1). Further studies of rituximab in autoantibody associated PNS are warranted.
- Subjects
RITUXIMAB; ANTINEOPLASTIC agents; PARANEOPLASTIC syndromes; MONOCLONAL antibodies; B cell lymphoma; AUTOIMMUNE diseases; LYMPHOMAS
- Publication
Journal of Neurology, 2006, Vol 253, Issue 1, p16
- ISSN
0340-5354
- Publication type
Article
- DOI
10.1007/s00415-005-0882-0